Search results for "Genetic therapy"

showing 10 items of 121 documents

Gene therapy using IL 12 family members in infection, auto immunity, and cancer.

2009

Interleukin-12 (IL-12) is known for several years to have an essential role in inflammatory responses and innate resistance to infection and cancer. This has been largely attributed to its ability to initiate the differentiation of T-helper-1 (Th1) cells producing interferon-gamma. Recently, two new cytokines, IL-23 and IL-27, with homology to IL-12 were discovered and assigned to the IL-12 family of cytokines. Growing evidence supports a role for IL-23 as key mediator of autoimmune disease regulating the new Th17 subset of CD4+ T cells. IL-27 can have pro- and anti-inflammatory effects, which increase Th1 differentiation, suppress Th2 proliferation, or stimulate cytotoxic T cell activity. …

CD4-Positive T-Lymphocytesmedicine.medical_treatmentGenetic enhancementAutoimmunityBiologymedicine.disease_causeInfectionsInterleukin-23AutoimmunityAutoimmune DiseasesMiceImmunityNeoplasmsDrug DiscoveryGeneticsmedicineCytotoxic T cellAnimalsHumansMolecular BiologyGenetics (clinical)Autoimmune diseaseClinical Trials as TopicInterleukinsCancerGenetic TherapyTh1 Cellsmedicine.diseaseInterleukin-12CytokineImmunologyInterleukin 12Molecular MedicineTh17 CellsCurrent gene therapy
researchProduct

Allergic contact dermatitis: understanding the immune response and potential for targeted therapy using cytokines.

1997

Allergic contact dermatitis is the most common job-related disease of the western world. The only available treatments are avoidance of contact with the allergen and the use of potent corticosteroids. Recently, the role of cytokines in the pathogenesis of this disease has been studied and, besides defining the key molecules and basic cellular immune responses responsible for disease development, these studies might help to develop new therapeutic strategies to target cytokines and thereby try to alter or abrogate ongoing immune reactions.

CD4-Positive T-Lymphocytesmedicine.medical_treatmentT-LymphocytesDiseaseCD8-Positive T-Lymphocytesmedicine.disease_causeLymphocyte ActivationTargeted therapyPathogenesisMiceImmune systemAllergenGeneticsmedicineAnimalsHumansRNA AntisenseAllergic contact dermatitisbusiness.industryDendritic CellsGenetic Therapymedicine.diseaseLangerhans CellsImmunologyDermatitis Allergic ContactMolecular MedicineCytokinesImmune reactionbusinessMolecular medicine today
researchProduct

The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy.

2000

Acetaminophen is oxidized by human CYP1A2 to the cytotoxic metabolite N-acetylbenzoquinoneimine (NABQI). Incubation of cells transfected with human CYP1A2 (H1A2 MZ cells) with 4-20 mM acetaminophen for 6 hours at 37 degrees C caused extensive cytotoxicity (cell viability10%). In contrast, nontransfected V79 MZ cells were unaffected (viability95%). By mixing H1A2 MZ cells with V79 MZ cells in various proportions and incubating with 4 mM acetaminophen, it was shown that the NABQI released from H1A2 MZ cells also caused cytotoxicity of bystander cells. Thus, in a mixture containing 5% H1A2 MZ cells, exposure to 4 mM acetaminophen for 6 hours resulted in complete cell killing by 24 hours. A sim…

Cancer ResearchCell SurvivalPharmacologyTransfectionCatalysisCell LineCricetulusCytochrome P-450 CYP1A2CricetinaemedicineTumor Cells CulturedCytotoxic T cellAnimalsHumansProdrugsViability assayCytotoxicityMolecular BiologyAcetaminophenChemistryCYP1A2TransfectionGenetic TherapyProdrugAcetaminophenCell killingMolecular Medicinemedicine.drugCancer gene therapy
researchProduct

miRNAs and their potential for use against cancer and other diseases

2007

miRNAs are 19–24 nucleotide long noncoding RNAs found in almost all genetically dissected species, including viruses, plants, nematodes, flies, fish, mice and humans. Rapid advances have been made in understanding their physiological functions, while abnormal patterns of miRNA expression have been found in many disease states, most notably human cancer. It is now clear that miRNAs represent a class of genes with a great potential for use in diagnosis, prognosis and therapy. In this review we will focus on the discoveries that elucidate their crucial role in mammalian diseases, particularly in cancer, and propose that miRNA-based gene therapy might become the potential technology of choice …

Cancer ResearchGenetic enhancementGenetic TherapyGeneral MedicineDiseaseComputational biologyBiologyPrognosisBioinformaticsMicroRNAsOncologyMirna expressionNeoplasmsmicroRNAAnimalsHumansPersonalized therapyGeneHuman cancerFuture Oncology
researchProduct

Antitumor effect of B16 melanoma cells genetically modified with the angiogenesis inhibitor rnasin.

2001

The growth of new blood vessels is an essential condition for the development of tumors with a diameter greater than 1-2 mm and also for their metastatic dissemination. RNasin, the placental ribonuclease inhibitor, is known to have antiangiogenic activity through the inhibition of angiogenin and basic fibroblast growth factor. Nevertheless, the administration of the recombinant form of a protein poses several limitations; as a result, we have studied the antitumor effect of RNasin in a murine gene therapy model. RNasin cDNA was subcloned into the pcDNA3 expression vector, and the resulting recombinant plasmid was used to transfect the B16 murine melanoma cell line. An RNasin inverted constr…

Cancer ResearchLung NeoplasmsAngiogeninTranscription GeneticGenetic enhancementCellBasic fibroblast growth factorGenetic VectorsMelanoma ExperimentalGene ExpressionAngiogenesis InhibitorsTransfectionNeovascularizationImmunoenzyme Techniqueschemistry.chemical_compoundMiceRibonucleasesmedicineTumor Cells CulturedAnimalsHumansRNA MessengerEnzyme InhibitorsMolecular BiologyDNA PrimersNeovascularization PathologicReverse Transcriptase Polymerase Chain ReactionMelanomaGenetic Therapymedicine.diseaseAngiogenesis inhibitormedicine.anatomical_structurechemistryCell cultureCancer researchMolecular Medicinemedicine.symptomPlacental HormonesCell DivisionCancer gene therapy
researchProduct

Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy

2003

Since neural progenitor cells can engraft stably into brain tumors and differentiate along the neuronal and glial line, we tested the hypothesis that transplanted cytosine deaminase (CD)-expressing ST14A cells (an immortalized neural progenitor cell line) can convert locally 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU) and produce a regression of glioma tumors. ST14A, retrovirally transduced with the E. coli CD gene, showed a strong bystander effect on glioma cells as assessed by in vitro assay. Intracerebral injection of C6 glioma cells generated a rapidly growing tumoral mass. DiI prelabeled ST14A, coinjected into the rat brain with C6 glioma cells, survived in the tumoral mass up t…

Cancer ResearchPathologymedicine.medical_specialtyGenetic enhancementBrain tumorFlucytosineBiologyTransfectionCytosine DeaminaseRats Sprague-DawleyGliomamedicineEscherichia coliAnimalsProdrugsProgenitor cellMolecular BiologyCells CulturedNeuronsBrain NeoplasmsStem CellsCytosine deaminaseTransfectionGenetic TherapyGliomamedicine.diseaseNeural stem cellRatsTransplantationMolecular MedicineFluorouracilStem Cell Transplantation
researchProduct

CD83+ human dendritic cells transfected with tumor peptide cDNA by electroporation induce specific T-cell responses: A potential tool for gene immuno…

2000

Dendritic cells (DC) are the most potent immunostimulatory cells, with the capacity to induce primary T-cell responses. Functional autologous DC can be generated from fetal calf serum-free peripheral blood mononuclear cells in the presence of interleukin-4 and granulocyte-macrophage colony-stimulating factor and are stimulated with a defined cytokine cocktail for terminal maturation. We were able to establish a nonviral transfection protocol for these DC by electroporation. Using enhanced green fluorescent protein as a reporter gene, we achieved transfection efficiencies of up to 10%. FACScan analyses revealed a stable phenotype, and the expression of major histocompatibility complex class …

Cancer Researchanimal structuresDNA Complementaryvirusesmedicine.medical_treatmentT cellT-LymphocytesGreen Fluorescent ProteinsImmunoglobulinsTransfectionGreen fluorescent proteinAntigens CDGenes ReportermedicineHumansMolecular BiologyCells CulturedReporter geneMembrane GlycoproteinsChemistryElectroporationfungiGranulocyte-Macrophage Colony-Stimulating FactorImmunotherapyTransfectionDendritic CellsGenetic TherapyFlow CytometryMolecular biologyRecombinant ProteinsLuminescent ProteinsCytokinemedicine.anatomical_structureElectroporationembryonic structuresMolecular MedicineImmunotherapyInterleukin-4Clone (B-cell biology)Cancer gene therapy
researchProduct

Cardioprotection by gene therapy: A review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of…

2015

Ischemic heart disease remains the leading cause of death worldwide. Ischemic pre-, post-, and remote conditionings trigger endogenous cardioprotection that renders the heart resistant to ischemic-reperfusion injury (IRI). Mimicking endogenous cardioprotection by modulating genes involved in cardioprotective signal transduction provides an opportunity to reproduce endogenous cardioprotection with better possibilities of translation into the clinical setting. Genes and signaling pathways by which conditioning maneuvers exert their effects on the heart are partially understood. This is due to the targeted approach that allowed identifying one or a few genes associated with IRI and cardioprote…

CardiotoxinIschemic heart diseaseCardiologyMyocardial IschemiaPreconditioningMyocardial Reperfusion InjuryCardioprotectionRemote conditioningCardiotoxinsPostconditioningGene therapyMedicalHumansMyocardialIschemic PreconditioningSocieties MedicalCardioprotection; Gene therapy; Genomics; Ischemic heart disease; Postconditioning; Preconditioning; Remote conditioning; Cardiology; Cardiotoxicity; Cardiotoxins; Gene Targeting; Genetic Therapy; Humans; Ischemic Preconditioning Myocardial; Italy; Myocardial Ischemia; Myocardial Reperfusion Injury; Oxidative Stress; Societies MedicalCardioprotection; Gene therapy; Genomics; Ischemic heart disease; Postconditioning; Preconditioning; Remote conditioning; Cardiology; Cardiotoxicity; Cardiotoxins; Gene Targeting; Genetic Therapy; Humans; Ischemic Preconditioning; Myocardial; Italy; Myocardial Ischemia; Myocardial Reperfusion Injury; Oxidative Stress; Societies; Medical; Cardiology and Cardiovascular MedicineOxidative StreGenomicsGenetic TherapyCardioprotection Gene therapy Genomics Ischemic heart disease Postconditioning Preconditioning Remote conditioningCardiotoxicityOxidative StressCardioprotection; Gene therapy; Genomics; Ischemic heart disease; Postconditioning; Preconditioning; Remote conditioningItalyIschemic Preconditioning MyocardialGene TargetingGenomicSocietiesCardiology and Cardiovascular MedicineHuman
researchProduct

MicroRNA-Based Therapeutic Perspectives in Myotonic Dystrophy

2019

Myotonic dystrophy involves two types of chronically debilitating rare neuromuscular diseases: type 1 (DM1) and type 2 (DM2). Both share similarities in molecular cause, clinical signs, and symptoms with DM2 patients usually displaying milder phenotypes. It is well documented that key clinical symptoms in DM are associated with a strong mis-regulation of RNA metabolism observed in patient’s cells. This mis-regulation is triggered by two leading DM-linked events: the sequestration of Muscleblind-like proteins (MBNL) and the mis-regulation of the CUGBP RNA-Binding Protein Elav-Like Family Member 1 (CELF1) that cause significant alterations to their important functions in RNA processing. It ha…

Context (language use)miRNA-based drugReviewBioinformaticsMyotonic dystrophyCatalysislcsh:ChemistryInorganic ChemistryMBNL proteinsCELF1microRNADrug DiscoveryMedicineAnimalsHumansPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopyCELF1 ProteinRna processingmyotonic dystrophymicroRNAbusiness.industryOrganic ChemistryAlternative splicingmiRNA-targeting drugRNA-Binding ProteinsGeneral MedicineGenetic Therapymedicine.diseasePhenotypeComputer Science ApplicationsAlternative SplicingMicroRNAslcsh:Biology (General)lcsh:QD1-999Drug developmentGene Expression Regulationantisense oligonucleotidesbusinessFunction (biology)International Journal of Molecular Sciences
researchProduct

Comparative Antitumor Effect of Preventive versus Therapeutic Vaccines Employing B16 Melanoma Cells Genetically Modified to Express GM-CSF and B7.2 i…

2012

Cancer vaccines have always been a subject of gene therapy research. One of the most successful approaches has been working with genetically modified tumor cells. In this study, we describe our approach to achieving an immune response against a murine melanoma model, employing B16 tumor cells expressing GM-CSF and B7.2. Wild B16 cells were injected in C57BL6 mice to cause the tumor. Irradiated B16 cells transfected with GM-CSF, B7.2, or both, were processed as a preventive and therapeutic vaccination. Tumor volumes were measured and survival curves were obtained. Blood samples were taken from mice, and IgGs of each treatment group were also measured. The regulatory T cells (Treg) o…

Cytotoxicity Immunologicnon-viralHealth Toxicology and MutagenesisGenetic enhancementMelanoma Experimentallcsh:MedicineToxicologyTransfectionT-Lymphocytes RegulatoryImmunoglobulin GArticleMiceImmune systemCell Line TumormedicineAnimalsbiologylcsh:RGene Transfer TechniquesCancerGranulocyte-Macrophage Colony-Stimulating FactorGM-CSFTransfectionGenetic Therapymedicine.diseaseSurvival Analysisgene therapyGenetically modified organismVaccinationMice Inbred C57BLGranulocyte macrophage colony-stimulating factorB7.2Immunoglobulin GImmunologybiology.proteinB7-2 AntigenNeoplasm Transplantationcancer vaccinesmedicine.drugToxins
researchProduct